See the DrugPatentWatch profile for Ubrelvy
Ubrelvy (ubrogepant) patent expiration is expected in 2033 [1]. DrugPatentWatch.com tracks patent information for pharmaceutical products, including Ubrelvy.
When does Ubrelvy lose its market exclusivity?
Ubrelvy is expected to lose its market exclusivity in 2033, following the expiration of its primary patents. This timeline is subject to change based on patent challenges and other legal proceedings.
Are there any ongoing patent challenges for Ubrelvy?
Information regarding specific patent challenges for Ubrelvy is not detailed here, but patent expiration dates can be influenced by legal disputes over patent validity and infringement.
What is Ubrelvy used for?
Ubrelvy is a medication used for the acute treatment of migraine with or without aura in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist.
What are the active ingredients in Ubrelvy?
The active ingredient in Ubrelvy is ubrogepant [1].
How does Ubrelvy work?
Ubrelvy works by blocking the activity of calcitonin gene-related peptide (CGRP) at its receptor. CGRP is a molecule that plays a role in migraine pain. By blocking CGRP, ubrogepant helps to reduce migraine symptoms [1].
What are the alternatives to Ubrelvy for migraine treatment?
Alternative treatments for acute migraine treatment include triptans, other CGRP antagonists, and pain relievers like NSAIDs [2].
How is Ubrelvy priced?
Pricing information for Ubrelvy can vary depending on insurance coverage and pharmacy. For specific pricing details, consumers should consult their pharmacy or insurance provider.
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [1].
What is the difference between Ubrelvy and other CGRP inhibitors?
While Ubrelvy is an oral CGRP receptor antagonist, other CGRP-targeting therapies include gepants (oral or injectable) and monoclonal antibodies (injectable) that target the CGRP ligand or its receptor. These different mechanisms and administration routes can lead to varying efficacy and side effect profiles.
What clinical trials have been conducted for Ubrelvy?
Clinical trials for Ubrelvy have evaluated its safety and efficacy in the acute treatment of migraine. These studies typically assess pain freedom, loss of the most bothersome symptom, and sustained pain freedom at 24 and 48 hours post-dose.
Sources:
1. DrugPatentWatch.com
2. Ubrelvy Prescribing Information